I emailed Todd yesterday and he called. Todd is v

I emailed Todd yesterday and he called. Todd is very detailed in explaining very little. That's his job. However, my take is that the big hurdle is approval of the S-1. Generex is borrowing bits of money to keep the lights on, but uplisting, the NGIO dividends, possible purchases, and R&D are dependent on funds from the S-1. MMPJoe has refused more toxic forms of funding that have been offered.

A lot of work went into the BARDA application and Todd believed it was well written. Application for COVID-19 funds from other companies have been made. Maybe Canada?

Joe is working his hardest to get the initiatives completed, but it just can't be done without money. He could not tell my why the S-1 has been held up, or if it has been held up at all. Perhaps all things Washington have been set back due to COVID-19 (JMO).

10-Q may reflect some earnings, but I didn't get the impression they would blow the doors off. No update available regarding Zhonghong COVID deal. Should some of their entities show they can survive on their own, they may be spun off. Todd said this was in the 10-K, but I missed it.

I think we can assume that no PR's will be issued unless there is something significant to report. When S-1 is approved, subsequent movement with the other initiatives should be rapid.

That's the best that I can recall from a verbal conversation. It's difficult to remember everything that was discussed. Take away is S-1, S-1, S-1. That is not to say other things aren't happening and other sources of funding have not been explored, but any real news we expect is going to be contingent upon approval of the S-1.